Our leadership team is composed of proven executives each passionate about transforming cancer care for patients everywhere.
Helmy Eltoukhy, PhD
Chairman and co-Chief Executive Officer
Helmy is an entrepreneur and pioneer in the biotech industry. After receiving his PhD, MS and BS degrees in electrical engineering from Stanford University, he joined the Stanford Genome Technology Center (SGTC) as a post-doctoral fellow in 2006 to work on low-cost DNA sequencing technologies. During his doctoral studies and at the SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-generation sequencing under several NHGRI grants. In 2007, he co-founded Avantome to commercialize semiconductor sequencing to help speed up the democratization of high throughput DNA sequencing until its acquisition by Illumina in August 2008. At Illumina, Helmy was Senior Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems.
AmirAli Talasaz, PhD
Co-Chief Executive Officer
AmirAli is an entrepreneur in the rare genomics and clinical diagnostics fields. Prior to co-founding Guardant, he was Senior Director of Diagnostics Research at Illumina and led the efforts for emerging clinical applications of next-generation genomic analysis. During that time, he developed different genomic technologies suitable for clinical applications. Before Illumina, he founded Auriphex Biosciences, which focused on purification and genetic analysis of circulating tumor cells for cancer management. The technology was acquired by Illumina in 2009. During his academic years, he led the Technology Development group at Stanford Genome Technology Center. AmirAli received his PhD in electrical engineering and MSc in management science from Stanford University.